indaptus_logo.png
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
04 janv. 2024 08h00 HE | Indaptus Therapeutics
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform...